Lyell Immunopharma, Inc. (LYEL) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 39.87M USD | Liabilities, Current |
| Cash and equivalents | 72.98M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 131.12M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $39.87M | $72.98M | $131.12M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $36.95M | $90.77M | $163.25M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $49.41M | $60.18M | $187.04M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $31.88M | $123.58M | $196.05M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $36.90M | $98.80M | $177.99M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $41.28M | $120.33M | $180.85M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $53.79M | $105.60M | $264.93M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $33.51M | $100.30M | $340.25M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $30.88M | $133.42M | $357.69M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $32.35M | $125.65M | $400.65M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $34.52M | $145.65M | $400.58M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $35.06M | $286.21M | $289.22M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $34.39M | $224.37M | $371.38M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $30.80M | $109.43M | $503.34M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $37.03M | $123.55M | $516.60M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $51.22M | $116.31M | $531.82M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $50.29M | $205.74M | $449.82M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $41.05M | $222.60M | $391.32M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $46.74M | $293.83M | $320.97M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $59.28M | $393.50M | $225.42M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $63.66M | $564.44M | $260.08M | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $244.37M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $49.28M | $140.41M | $472.21M | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $134.41M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $245.95M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $96.67M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |